A Novel 1,3-Beta-d-Glucan Inhibitor, Ibrexafungerp (Formerly SCY-078), Shows Potent Activity in the Lower pH Environment of Vulvovaginitis

Ibrexafungerp (IBX) (formerly SCY-078) is a novel glucan synthase inhibitor whose oral availability is being evaluated for efficacy against vulvovaginal candidiasis (VVC). Bioavailability and in vitro activity are important efficacy indicators, but accepted susceptibility methods do not always accur...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Antimicrob Agents Chemother
Main Authors: Larkin, E. L., Long, L., Isham, N., Borroto-Esoda, K., Barat, S., Angulo, D., Wring, S., Ghannoum, M.
Format: Artigo
Sprog:Inglês
Udgivet: American Society for Microbiology 2019
Fag:
Clinical Therapeutics
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6496072/
https://ncbi.nlm.nih.gov/pubmed/30885896
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02611-18
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker